Gate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
Ironwood Pharmaceuticals (NASDAQ: IRWD) stock surged approximately 36% in pre-market trading after the company issued a 2026 financial guidance that far exceeded Wall Street expectations. The biotech company projects total revenue to reach $450 million to $475 million, well above the market consensus of $319.5 million, and expects adjusted EBITDA to exceed $300 million. This optimistic outlook is primarily driven by strategic price reductions for its flagship drug LINZESS, which is expected to improve net pricing and boost net sales in the US to $1.125 billion to $1.175 billion.